In Brief: Genetics Institute/Pharmacia & Upjohn ReFacto
Executive Summary
Genetics Institute/Pharmacia & Upjohn ReFacto: American Home Products subsidiary GI acquires development and commercialization rights to P&U's recombinant factor VIII for the treatment of hemophilia A. GI will continue clinical development of ReFacto, currently in Phase III trials. P&U will perform selected development activities and manufacture the product for GI. P&U retains rights to co-promote ReFacto in Scandanavia and the Middle East...